# Lupin sales jump 33% as pharma majors pivot to India, emerging markets 2026-08-07T21:04:24+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 1 independent outlet Lupin posted a 33.3% year-on-year sales jump to ₹8,217 crore in Q1 FY27, with EBITDA rising 42.8% to ₹2,580 crore and profit after tax up 16% to ₹1,417 crore. The company attributed the strong start to robust growth across the US, India, other developed markets and emerging markets, along with continued profitability improvement. The results come amid a broader shift in the pharma sector. According to The Hindu Business Line, Sun Pharma, Aurobindo Pharma and Dr Reddy’s Laboratories showed divergent performances. Sun Pharma’s sales rose 10% to ₹15,184 crore, driven by India formulations and innovative medicines, while its US formulations fell 9.7%. Aurobindo posted 16.3% revenue growth to ₹9,150 crore. Dr Reddy’s, however, saw revenue drop 5.6% to ₹8,071 crore and profit plunge 69% due to lack of lenalidomide sales and a ₹240-crore semaglutide provision. The Business Line notes that domestic branded formulations, innovative medicines and emerging markets are increasingly cushioning Indian drugmakers against US market volatility. ## Coverage - businesstoday.in - thehindubusinessline.com Tags: Lupin, pharma results, profit, Q1 FY27, sales growth Canonical: https://indianopinion.org/lupin-q1-sales-surge-33-to-rs-8217-crore/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/lupin-q1-sales-surge-33-to-rs-8217-crore/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes.